The global hair treatment drug market was valued at approximately $1.4 billion in 2023 and is expected to reach around $2.99 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.14% from 2024 to 2034. This growth is primarily driven by the rising prevalence of hair loss, increased research and development efforts, and growing investments in the sector.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5306

Hair Treatment Drug Market A New Era in Hair Care

Hair loss is a common issue, with people losing more than 100 strands of hair each day. While effective treatments are available for certain types of hair loss, there are several different conditions that can cause it. These include androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, hypotrichosis, lichen planopilaris, and discoid lupus erythematosus, among others. Thankfully, many of these conditions can be treated with medications. Over-the-counter (OTC) options often include natural compounds like biotin, zinc, collagen, azelaic acid, and oils such as tea tree oil.

When OTC treatments aren’t enough, doctors may prescribe stronger medications like minoxidil, finasteride, spironolactone (an antiandrogen), oral contraceptives, corticosteroids, or antifungal drugs, depending on the type and severity of the hair loss.

The rising number of hair loss cases is driving the demand for hair treatment drugs. Hair loss affects both men and women of all ages, often due to factors like hormonal imbalances, immune disorders, pollution, and drug-induced hair loss. This growing issue, along with ongoing research into new treatments, is fueling the market’s expansion.

Hair Treatment Drug Market Trends

• July 2024: Sun Pharma received approval from the US FDA for LEQSELVI (deuruxolitinib), a groundbreaking JAK inhibitor used to treat severe alopecia areata. This approval followed Sun Pharma’s $576 million acquisition of Concert Pharmaceuticals.
• February 2024: The National Institute for Health and Care Excellence (NICE) recommended Ritlecitinib, a newly approved drug, for use by the NHS in treating severe alopecia.
• June 2022: The US FDA approved Baricitinib (Olumiant), an oral treatment for alopecia areata in adults, developed by Eli Lilly.
• Fiscal Q1 2024: Cipla reported a strong performance with a 18.3% increase in net profits, totaling $140.8 million. The company’s revenue also grew by 7%, driven largely by a surge in sales in North America.

Recent Developments in the Hair Treatment Drug Market

In October 2024, researchers at Harvard Medical School introduced an innovative microneedle patch system designed to deliver treatment directly to affected areas of the skin in animal models. This new system works by regulating the immune response and holds significant promise as a potential treatment for alopecia areata, as well as other conditions that require targeted immune system modulation.

In March 2024, a team from Yokohama National University in Japan explored the role of cinnamic acid, a small molecule that can activate oxytocin receptor expression, to promote hair growth in human hair follicles. The study showed promising results, indicating that products targeting oxytocin could become a new approach for promoting hair growth.

Key Companies in the Hair Treatment Drug Market

• 3S Bio, Inc.: A biotechnology company that focuses on the development and commercialization of innovative treatments for hair loss, particularly using biologics and small molecules.
• AbbVie: A global biopharmaceutical company, AbbVie is known for its wide range of medical solutions. The company has been involved in hair loss treatments, particularly through its work on autoimmune-related alopecia areata therapies.
• Aclaris Therapeutics, Inc.: A biopharmaceutical company specializing in developing treatments for dermatological conditions, including hair loss disorders. Aclaris is focused on researching new drug candidates for alopecia areata and androgenetic alopecia.
• Cipla, Inc.: A multinational pharmaceutical company based in India, Cipla has a strong presence in the hair treatment market. The company offers treatments for various hair loss conditions, especially in the global markets of North America and Asia.
• Daiichi Sankyo: A major Japanese pharmaceutical company involved in the research and development of therapies for various medical conditions, including hair loss. The company has been working on treatments for autoimmune disorders that cause hair loss.
• Dr. Reddy’s Laboratories: An Indian multinational pharmaceutical company, Dr. Reddy’s is involved in the production and development of generic drugs and biosimilars, including products aimed at treating hair loss and related conditions.
• Eli Lilly & Co.: A global leader in the pharmaceutical industry, Eli Lilly developed Baricitinib (Olumiant), the first oral treatment approved by the US FDA for alopecia areata, marking a significant advancement in hair loss treatment options.
• Follicum AB: A Swedish biopharmaceutical company focused on developing treatments for hair loss, with a particular emphasis on targeting the hair follicle regeneration process. The company is working on developing peptide-based therapies for hair growth.
• GlaxoSmithKline plc (GSK): A multinational pharmaceutical company with a broad portfolio that includes treatments for various hair loss conditions, including its ongoing research into novel approaches for managing alopecia areata.
• Incyte Corporation: A biopharmaceutical company with a focus on immunology and oncology, Incyte has made strides in developing targeted therapies for conditions like alopecia areata. The company is actively involved in research into JAK inhibitors for hair loss.
• Johnson & Johnson: One of the largest healthcare companies globally, Johnson & Johnson offers a wide range of products, including those for hair health. The company is involved in the development of both over-the-counter and prescription hair loss treatments.
• Merck & Co., Inc.: A leading global pharmaceutical company, Merck has developed a number of therapies targeting autoimmune diseases and is researching ways to expand its portfolio to address conditions like alopecia areata.
• Pharmacos: A pharmaceutical company focused on dermatological treatments, Pharmacos is involved in the development of topical treatments and solutions for various hair loss conditions.
• Sun Pharmaceutical Industries, Ltd.: An Indian multinational pharmaceutical company, Sun Pharma has expanded its portfolio in the hair loss treatment market, particularly through its acquisition of Concert Pharmaceuticals, which added new hair loss drug candidates to its pipeline.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hair-treatment-drug-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5306

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare